These are quite common when you first start taking oxybutynin.
Reproduction studies using oxybutynin chloride in the hamster, rabbit, rat, and mouse have shown no definite evidence of impaired fertility.
The most common adverse reactions reported during clinical trials by 5 of patients were dry mouth, constipation, diarrhoea, headache, somnolence and dizziness. Over the Counter Products Name Dosage Strength Route Labeller Marketing Start Marketing End. Affected organisms Humans and other mammals Pathways Not Available Pharmacogenomic Effects ADRs Browse all title About SNP Mediated Effects ADRs.
A severity rating for each drug interaction, from minor to major. Oxybutynin also directly relaxes the bladder s outer layer of muscle the detrusor muscle. Includes restrictions on co-administration, contraindicated populations, and more.
Ask your doctor before use if you are taking the following medications:
Some examples are allergy medicine, narcotic pain medicine, and alcohol.
This drug may harm or be fatal to your unborn baby.
Physicians may elect to use it if its benefits are judged to outweigh its potential risks.
Stopping suddenly can cause problems and your doctor will want you to reduce your dose gradually if you need to stop treatment.
This piperidyl side chain is not present in other phenothiazines, which in general exhibit much less evidence of retinal toxicity.
Early clinical medicine with oxybutynin proved promising, and a subsequent summary of 15 randomised controlled trials showed a mean 52 per cent decrease in incontinence and a mean 33 per cent reduction in frequency per 24 hours.
Oxybutynin is extensively metabolised by the liver, primarily by the cytochrome P450 enzyme system, particularly CYP 3A4 found mostly in the liver and gut wall. That means you need to take it with other drugs. This drug may cause you to be unable to empty your bladder if you have bladder outlet obstruction. But, if it is nearly time for your next dose, just take the next dose at the right time. Concomitant administration with a CYP 3A4 inhibitor can inhibit oxybutynin metabolism and increase oxybutynin exposure.